HC Wainwright Has Positive Forecast for SMMT Q1 Earnings

Summit Therapeutics PLC (NASDAQ:SMMT) – Equities researchers at HC Wainwright lifted their Q1 2026 EPS estimates for Summit Therapeutics in a research note issued to investors on Tuesday, February 24th. HC Wainwright analyst M. Kapoor now forecasts that the company will post earnings per share of ($0.30) for the quarter, up from their previous estimate of ($0.31). HC Wainwright currently has a “Buy” rating and a $30.00 target price on the stock. The consensus estimate for Summit Therapeutics’ current full-year earnings is ($0.30) per share. HC Wainwright also issued estimates for Summit Therapeutics’ Q3 2026 earnings at ($0.32) EPS, Q4 2026 earnings at ($0.33) EPS and FY2026 earnings at ($1.26) EPS.

Summit Therapeutics (NASDAQ:SMMT) last issued its quarterly earnings results on Monday, February 23rd. The company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.07).

A number of other research analysts have also recently commented on SMMT. Piper Sandler set a $40.00 price target on Summit Therapeutics in a research report on Wednesday, January 14th. Barclays upgraded shares of Summit Therapeutics from an “underweight” rating to an “equal weight” rating and increased their price objective for the stock from $16.00 to $18.00 in a research note on Wednesday, December 17th. Summit Redstone set a $18.00 target price on shares of Summit Therapeutics in a research report on Wednesday, December 17th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Summit Therapeutics in a report on Thursday, January 22nd. Finally, Zacks Research cut shares of Summit Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Wednesday, February 4th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, three have given a Hold rating and three have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Summit Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $32.25.

Summit Therapeutics Price Performance

Shares of NASDAQ SMMT opened at $16.59 on Friday. The business has a fifty day moving average price of $16.52 and a two-hundred day moving average price of $18.98. The stock has a market capitalization of $12.86 billion, a PE ratio of -11.44 and a beta of -1.44. Summit Therapeutics has a fifty-two week low of $13.83 and a fifty-two week high of $36.91.

Institutional Trading of Summit Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of SMMT. T. Rowe Price Investment Management Inc. lifted its stake in shares of Summit Therapeutics by 2,654.4% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,873 shares of the company’s stock valued at $33,000 after acquiring an additional 1,805 shares during the last quarter. Invesco Ltd. increased its holdings in Summit Therapeutics by 8.3% in the 4th quarter. Invesco Ltd. now owns 461,301 shares of the company’s stock worth $8,068,000 after purchasing an additional 35,226 shares in the last quarter. Beacon Pointe Advisors LLC increased its holdings in Summit Therapeutics by 10.9% in the 4th quarter. Beacon Pointe Advisors LLC now owns 39,611 shares of the company’s stock worth $693,000 after purchasing an additional 3,885 shares in the last quarter. Virtus Investment Advisers LLC raised its position in Summit Therapeutics by 168.3% in the fourth quarter. Virtus Investment Advisers LLC now owns 15,141 shares of the company’s stock valued at $265,000 after purchasing an additional 9,497 shares during the last quarter. Finally, Tudor Investment Corp ET AL boosted its stake in shares of Summit Therapeutics by 21.8% during the fourth quarter. Tudor Investment Corp ET AL now owns 423,084 shares of the company’s stock valued at $7,400,000 after purchasing an additional 75,843 shares in the last quarter. Institutional investors own 4.61% of the company’s stock.

About Summit Therapeutics

Summit Therapeutics plc is a clinical‐stage biotechnology company dedicated to the discovery and development of precision medicines for serious and life‐threatening diseases. The company applies a targeted approach to drug design, focusing on novel mechanisms of action that differentiate its candidates from existing therapies.

Summit’s lead asset, ridinilazole (formerly SMT19969), is being developed to treat Clostridioides difficile infections and has received both Fast Track and Qualified Infectious Disease Product designations from the U.S.